FibroGen (FGEN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

FibroGen Revenue Highlights

Latest Revenue (Y)

$29.62M

Latest Revenue (Q)

$50.64M

Main Segment (Y)

Drug Product Revenue

Main Geography (Y)

UNITED STATES

FibroGen Revenue by Period

FibroGen Revenue by Year

Date	Revenue	Change
2024-12-31	$29.62M	-79.95%
2023-12-31	$147.75M	4.99%
2022-12-31	$140.73M	-40.19%
2021-12-31	$235.31M	33.46%
2020-12-31	$176.32M	-31.28%
2019-12-31	$256.58M	20.48%
2018-12-31	$212.96M	69.46%
2017-12-31	$125.67M	-30.02%
2016-12-31	$179.58M	-0.69%
2015-12-31	$180.83M	31.41%
2014-12-31	$137.60M	34.68%
2013-12-31	$102.17M	54.96%
2012-12-31	$65.93M	-

FibroGen generated $29.62M in revenue during NA 2024, up -79.95% compared to the previous quarter, and up 11.54% compared to the same period a year ago.

FibroGen Revenue by Quarter

Date	Revenue	Change
2024-06-30	$50.64M	-9.41%
2024-03-31	$55.90M	105.99%
2023-12-31	$27.14M	-32.38%
2023-09-30	$40.13M	-9.44%
2023-06-30	$44.32M	22.56%
2023-03-31	$36.16M	5.22%
2022-12-31	$34.37M	118.41%
2022-09-30	$15.73M	-47.21%
2022-06-30	$29.81M	-51.00%
2022-03-31	$60.83M	267.69%
2021-12-31	$16.54M	-89.39%
2021-09-30	$155.97M	540.18%
2021-06-30	$24.36M	-36.60%
2021-03-31	$38.43M	-40.88%
2020-12-31	$65.00M	47.62%
2020-09-30	$44.03M	2.67%
2020-06-30	$42.89M	75.76%
2020-03-31	$24.40M	206.01%
2019-12-31	$7.97M	-75.96%
2019-09-30	$33.17M	-82.68%
2019-06-30	$191.57M	702.77%
2019-03-31	$23.86M	-77.92%
2018-12-31	$108.05M	272.25%
2018-09-30	$29.03M	-33.96%
2018-06-30	$43.95M	37.67%
2018-03-31	$31.93M	-24.90%
2017-12-31	$42.51M	55.87%
2017-09-30	$27.27M	-5.95%
2017-06-30	$29.00M	7.83%
2017-03-31	$26.89M	-15.73%
2016-12-31	$31.91M	6.01%
2016-09-30	$30.10M	-66.28%
2016-06-30	$89.28M	215.68%
2016-03-31	$28.28M	15.71%
2015-12-31	$24.44M	25.10%
2015-09-30	$19.54M	-83.79%
2015-06-30	$120.55M	639.66%
2015-03-31	$16.30M	1.20%
2014-12-31	$16.11M	17.88%
2014-09-30	$13.66M	-84.81%
2014-06-30	$89.96M	403.23%
2014-03-31	$17.88M	44.28%
2013-12-31	$12.39M	-82.61%
2013-09-30	$71.25M	-

FibroGen generated $50.64M in revenue during Q2 2024, up -9.41% compared to the previous quarter, and up 140.04% compared to the same period a year ago.

FibroGen Revenue Breakdown

FibroGen Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Drug Product Revenue	$27.67M	$18.75M	$11.09M	$962.00K	$8.91M
Product	-	-	-	-	$89.03M

FibroGen's latest annual revenue breakdown by segment (product or service), as of Dec 24: Drug Product Revenue (100.00%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19
Drug Product Revenue	$3.45M	$-262.00K	$24.49M	$1.05M	$1.32M	$14.27M	$2.11M	$6.48M	$1.09M	$7.59M	$1.13M	$8.48M	$686.00K	$8.24M	-	-	-	-
Product	-	$46.21M	$30.54M	$29.39M	$35.92M	$27.90M	$19.83M	$5.37M	$579.00K	-	-	-	-	-	-	-	-	-
License	-	-	-	$2.65M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-	-	$200.00K	-	-	-	-	-	-	-	-	-

FibroGen's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Drug Product Revenue (100.00%).

FibroGen Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
UNITED STATES	$26.11M	$12.96M	$12.52M	$46.12M	-
CHINA	$91.00K	$109.38M	$84.63M	$55.64M	$72.50M
Europe	$6.27M	$9.55M	$33.82M	$131.24M	$67.16M
JAPAN	$-2.85M	$15.87M	$9.76M	$2.31M	$36.66M
All Other	-	-	-	-	-

FibroGen's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (88.16%), Europe (21.17%), CHINA (0.31%), and JAPAN (-9.64%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23
CHINA	-	$4.50M	$2.10M	$104.38M	$4.70M	$300.00K

FibroGen Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BMRN	BioMarin Pharmaceutical	$2.85B	$733.87B
BPMC	Blueprint Medicines	$508.82M	$128.18M
ARDX	Ardelyx	$333.62M	$98.24M
DAWN	Day One Biopharmaceuticals	$131.16M	$20.07M
GOSS	Gossamer Bio	$114.70M	$9.48M
GLUE	Monte Rosa Therapeutics	$75.62M	$4.70M
STRO	Sutro Biopharma	$62.04M	$25.71M
STOK	Stoke Therapeutics	$36.55M	$4.89M
AGIO	Agios Pharmaceuticals	$36.50M	$8.96M
MRUS	Merus	$36.13M	$11.77M
FGEN	FibroGen	$29.62M	$50.64M
SNDX	Syndax Pharmaceuticals	$23.68M	$12.50M
VSTM	Verastem	$10.00M	$10.00M
CGEM	Cullinan Oncology	-	-
AKRO	Akero Therapeutics	-	-
PCVX	Vaxcyte	-	-
RVMD	Revolution Medicines	-	-
ZURA	Zura Bio	-	-
HEPA	Hepion Pharmaceuticals	-	-
BMEA	Biomea Fusion	-	-
LYEL	Lyell Immunopharma	-	$34.00K
LRMR	Larimar Therapeutics	-	-
MREO	Mereo BioPharma Group	-	-

FGEN Revenue FAQ

What is FibroGen’s yearly revenue?

FibroGen's yearly revenue for 2024 was $29.62M, representing a decrease of -79.95% compared to 2023. The company's yearly revenue for 2023 was $147.75M, representing an increase of 4.99% compared to 2022. FGEN's yearly revenue for 2022 was $140.73M, representing a decrease of -40.19% compared to 2021.

What is FibroGen’s quarterly revenue?

FibroGen's quarterly revenue for Q2 2024 was $50.64M, a -9.41% decrease from the previous quarter (Q1 2024), and a 14.26% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $55.9M, a 105.99% increase from the previous quarter (Q4 2023), and a 54.59% increase year-over-year (Q1 2023). FGEN's quarterly revenue for Q4 2023 was $27.14M, a -32.38% decrease from the previous quarter (Q3 2023), and a -21.03% decrease year-over-year (Q4 2022).

What is FibroGen’s revenue growth rate?

FibroGen's revenue growth rate for the last 3 years (2022-2024) was -78.95%, and for the last 5 years (2020-2024) was -83.20%.

What are FibroGen’s revenue streams?

FibroGen's revenue streams in c 24 are Drug Product Revenue

What is FibroGen’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of FibroGen was Drug Product Revenue. This segment made a revenue of $27.67M, representing 100.00% of the company's total revenue.